Back to search
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Depressive Disorder, Major
Clinicaltrials.gov:
Other:
#42847922MDD3011
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Depressive Disorder, Major
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
Placebo
Seltorexant
Age
18 to 74 years old
Biological sex
All
Placebo?
Yes
Trial start date
April 30, 2026
Trial end date
May 3, 2029
CT.gov ID
#NCT07573176
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Brazil,
- Canada,
- China,
- Malaysia,
- Taiwan,
- United States
Loading...
Enrolling
Snellville, Georgia, United States, 30078
Enrolling
Boston, Massachusetts, United States, 02116
Enrolling
New York, New York, United States, 10029
Enrolling
Watertown, Massachusetts, United States, 02472
Enrolling
Atlanta, Georgia, United States, 30328
Enrolling
Clinton, Utah, United States, 84015
Enrolling
São Paulo, Brazil, 01236030
Enrolling
Glendale, California, United States, 91206
Enrolling
Beijing, China, 102208
Enrolling
Mount Kisco, New York, United States, 10549
Enrolling
Bellflower, California, United States, 90706
Enrolling
Marlton, New Jersey, United States, 08053
Enrolling
Riverside, California, United States, 92506
Enrolling
São Bernardo do Campo, Brazil, 09726 150
Enrolling
Chicago, Illinois, United States, 60634
Enrolling
Taichung, Taiwan, 402
Enrolling
Edmond, Oklahoma, United States, 73013
Enrolling
Oceanside, California, United States, 92056
Enrolling
New York, New York, United States, 10017
Enrolling
Dallas, Texas, United States, 75251
Enrolling
West Palm Beach, Florida, United States, 33407
Enrolling
Tampa, Florida, United States, 33629
Enrolling
Salvador, Brazil, 40170 108
Enrolling
Brooklyn, New York, United States, 11229
Enrolling
Cary, North Carolina, United States, 27511
Enrolling
New York, New York, United States, 10036
Enrolling
North Vancouver, British Columbia, Canada, V7P2T4
Enrolling
Orange, California, United States, 92868
Enrolling
Bellevue, Washington, United States, 98007
Enrolling
Miami, Florida, United States, 33186
Enrolling
Cincinnati, Ohio, United States, 45215
Enrolling
Baltimore, Maryland, United States, 21208
Enrolling
Miami, Florida, United States, 33126
Enrolling
Kingston, Ontario, Canada, K7L 4X3
Enrolling
Hialeah, Florida, United States, 33012
Enrolling
Brooklyn, New York, United States, 11235
Enrolling
Bryant, Arkansas, United States, 72022
Enrolling
Oklahoma City, Oklahoma, United States, 73116
Enrolling
Walnut Creek, California, United States, 94596
Enrolling
Taipei, Taiwan, 10449
Enrolling
Taipei, Taiwan, 110
Enrolling
Taipei, Taiwan, 112
Enrolling
Doral, Florida, United States, 33178
Enrolling
Kuala Lumpur, Malaysia, 59100
Enrolling
Las Vegas, Nevada, United States, 89128
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
Key links
© Johnson & Johnson and its affiliates 2026
